| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NAT2 |
| Uniprot No | P11245 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-290aa |
| 氨基酸序列 | MDIEAYFERIGYKNSRNKLDLETLTDILEHQIRAVPFENLNMHCGQAMELGLEAIFDHIVRRNRGGWCLQVNQLLYWALTTIGFQTTMLGGYFYIPPVNKYSTGMVHLLLQVTIDGRNYIVDAGSGSSSQMWQPLELISGKDQPQVPCIFCLTEERGIWYLDQIRREQYITNKEFLNSHLLPKKKHQKIYLFTLEPRTIEDFESMNTYLQTSPTSSFITTSFCSLQTPEGVYCLVGFILTYRKFNYKDNTDLVEFKTLTEEEVEEVLKNIFKISLGRNLVPKPGDGSLTI |
| 预测分子量 | 49.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NAT2重组蛋白的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*"Expression and Functional Characterization of Human Arylamine N-Acetyltransferase 2 (NAT2) Genetic Variants in Escherichia coli"*
**作者**：Zang Y, et al.
**摘要**：该研究通过在大肠杆菌中表达多种NAT2基因多态性变异的重组蛋白，分析了不同单核苷酸多态性(SNP)对酶活性和稳定性的影响，揭示了部分变异导致乙酰化能力降低的机制。
---
2. **文献名称**：*"Structural and Functional Analysis of Human NAT2 Reveals Substrate-Specific Acetylation Patterns"*
**作者**：Dupret JM, et al.
**摘要**：利用昆虫细胞系统表达并纯化人NAT2重组蛋白，结合酶动力学实验和分子对接技术，阐明了NAT2对不同底物(如异烟肼)的乙酰化选择性及结构基础。
---
3. **文献名称**：*"Development of a High-Yield Recombinant NAT2 Expression System for Drug Metabolism Studies"*
**作者**：Hein DW, et al.
**摘要**：报道了一种优化的哺乳动物细胞表达系统，成功制备高纯度NAT2重组蛋白，并应用于体外药物代谢模型，验证了其与临床药物代谢个体差异的相关性。
---
**备注**：以上文献为示例，实际引用时建议通过PubMed或Web of Science核实具体信息，并优先选择近五年内发表的高质量研究。
**Background of NAT2 Recombinant Protein**
N-acetyltransferase 2 (NAT2) is a phase II metabolic enzyme belonging to the arylamine N-acetyltransferase family, primarily expressed in the liver and gastrointestinal tract. It plays a critical role in the biotransformation of xenobiotics, including therapeutic drugs, carcinogens, and environmental toxins, by catalyzing the transfer of acetyl groups from acetyl-CoA to aromatic amines, hydrazines, and other substrates. This acetylation process influences the solubility, activity, and excretion of these compounds, thereby impacting drug efficacy and toxicity.
NAT2 is highly polymorphic, with genetic variations (e.g., single nucleotide polymorphisms, SNPs) leading to distinct acetylator phenotypes: rapid, intermediate, and slow. These phenotypes affect individual responses to medications such as isoniazid (anti-tuberculosis), sulfonamides (antibiotics), and procainamide (antiarrhythmic). Slow acetylators, for instance, are prone to drug accumulation and adverse effects due to reduced enzymatic activity. NAT2 polymorphisms also correlate with susceptibility to certain cancers (e.g., bladder, colorectal) and autoimmune diseases, highlighting its biomedical significance.
Recombinant NAT2 protein is engineered using heterologous expression systems (e.g., *E. coli*, mammalian cells) to study its structure-function relationships, substrate specificity, and interaction with inhibitors/activators. Purified recombinant NAT2 enables *in vitro* assays to assess enzymatic kinetics, genetic variant effects, and metabolic profiling of drugs/toxicants. Its production supports pharmacogenomic research, personalized medicine strategies, and toxicology studies, offering insights into interindividual variability in drug metabolism. Additionally, recombinant NAT2 aids in developing diagnostic tools to predict acetylator status and optimize therapeutic regimens, bridging genetic data with clinical outcomes.
In summary, NAT2 recombinant protein serves as a vital tool for unraveling the enzyme's role in metabolism, disease mechanisms, and precision medicine applications.
×
